Cancer Biotherapy and Radiopharmaceuticals , published 10 times a year in print and online, is under the editorial leadership of editors Donald J. Buchsbaum, Ph.D., and Robert K. Oldham, M.D., Lower... New Rochelle, NY, January 22, 2014-Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 can extend survival.
via New Rochelle Newswire http://ift.tt/1jnSR7Y
via New Rochelle Newswire http://ift.tt/1jnSR7Y
No comments:
Post a Comment